Jazz Pharmaceuticals
JAZZ
323 hedge funds and large institutions have $8.13B invested in Jazz Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 108 increasing their positions, 115 reducing their positions, and 41 closing their positions.
83% more funds holding in top 10
Funds holding in top 10: 6 → 11 (+5)
12% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 41
11% more capital invested
Capital invested by funds: $7.32B → $8.13B (+$808M)
0% more funds holding
Funds holding: 323 → 323 (0)
0.66% less ownership
Funds ownership: 90.8% → 90.14% (-0.66%)
6% less call options, than puts
Call options by funds: $31.7M | Put options by funds: $33.7M
6% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 115
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$167M |
| 2 |
O
OrbiMed
New York
|
+$63.4M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$38.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.1M |
| 5 |
Millennium Management
New York
|
+$28.4M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SBA
351
Seven Bridges Advisors
New York
| – | -$164K | -1,221 | Closed |
|
|
STA
352
Summit Trail Advisors
New York
| – | -$180K | -1,175 | Closed |
|
|
FANJ
353
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$135K | -1,000 | Closed |
|
354
Walleye Trading
New York
| – | -$137K | -932 | Closed |
|
|
BL
355
Balentine LLC
Atlanta,
Georgia
| – | -$68K | -507 | Closed |
|
|
AIS
356
AlphaOne Investment Services
West Chester,
Pennsylvania
| – | -$59K | -440 | Closed |
|
|
CA
357
Calton & Associates
Tampa,
Florida
| – | -$59K | -390 | Closed |
|
|
CG
358
Cutler Group
San Francisco,
California
| – | -$13K | -100 | Closed |
|
359
Bessemer Group
Woodbridge,
New Jersey
| – | -$11K | -81 | Closed |
|
|
SQA
360
Simon Quick Advisors
Morristown,
New Jersey
| – | -$7K | -49 | Closed |
|
|
BBHC
361
Brown Brothers Harriman & Co
New York
| – | -$6K | -45 | Closed |
|
|
WAP
362
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$2K | -13 | Closed |
|
|
CFA
363
Carroll Financial Associates
Charlotte,
North Carolina
| – | -$1K | -11 | Closed |
|
JAZZ Hedge Fund Activity: Q1 2018 in Review
323 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2018, worth a combined $8.13B — up 11% from $7.32B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new JAZZ positions and 41 closed out — a net gain of 5 holders — while 108 added to existing stakes and 115 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $167M. The largest seller was Putnam Investments, cutting an estimated $160M.
- 323 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $8.13B of Jazz Pharmaceuticals stock for Q1 2018, up 11% quarter-over-quarter.
- 46 funds opened new Jazz Pharmaceuticals positions in Q1 2018 and 41 closed out, a net change of +5 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2018 was PFM Health Sciences, an estimated $167M added.
- The largest Jazz Pharmaceuticals seller in Q1 2018 was Putnam Investments, an estimated $160M sold.
Based on aggregated 13F filings for Q1 2018.